WVE Reports $544.6M Cash, $19.2M Q1 Rev, +12% YoY, FDA Accepts INLIGHT Phase 2a, 2026 Milestones: WVE-007, WVE-006 Data, CTA Submission, Accelerated Approval Feedback
Wave Life Sciences Ltd. Ordinary Shares · PHARMACEUTICAL PREPARATIONS · Now $6.26
-6.2% in 1d after detection
Post-detection moves
1h
—
1d
-6.2%
3d
-2.7%
7d
-3.7%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS